Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:CALC NASDAQ:CYCN NASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.43-2.3%$3.94$1.19▼$85.80$3.32M-0.132.58 million shs421,119 shsCALCCalciMedica$0.86+1.2%$0.64$0.46▼$7.20$13.59M0.97792,847 shs156,163 shsCYCNCyclerion Therapeutics$3.06+1.9%$3.12$1.03▼$8.48$13.23M1.783.58 million shs34,567 shsPHIOPhio Pharmaceuticals$1.14+2.3%$1.18$0.81▼$4.19$13.19M0.822.27 million shs78,211 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+0.69%+7.35%-56.93%-58.40%-92.34%CALCCalciMedica+6.21%+14.18%+44.44%+28.62%-47.84%CYCNCyclerion Therapeutics-0.66%-4.76%-7.98%+115.83%-6.25%PHIOPhio Pharmaceuticals-0.89%+0.91%-2.63%-5.13%-46.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.43-2.3%$3.94$1.19▼$85.80$3.32M-0.132.58 million shs421,119 shsCALCCalciMedica$0.86+1.2%$0.64$0.46▼$7.20$13.59M0.97792,847 shs156,163 shsCYCNCyclerion Therapeutics$3.06+1.9%$3.12$1.03▼$8.48$13.23M1.783.58 million shs34,567 shsPHIOPhio Pharmaceuticals$1.14+2.3%$1.18$0.81▼$4.19$13.19M0.822.27 million shs78,211 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+0.69%+7.35%-56.93%-58.40%-92.34%CALCCalciMedica+6.21%+14.18%+44.44%+28.62%-47.84%CYCNCyclerion Therapeutics-0.66%-4.76%-7.98%+115.83%-6.25%PHIOPhio Pharmaceuticals-0.89%+0.91%-2.63%-5.13%-46.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 1.67Reduce$54.003,732.51% UpsideCALCCalciMedica 2.00Hold$10.001,112.12% UpsideCYCNCyclerion Therapeutics 1.00SellN/AN/APHIOPhio Pharmaceuticals 2.00Hold$14.001,144.44% UpsideCurrent Analyst Ratings BreakdownLatest ARTL, CYCN, CALC, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PHIOPhio Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ARTLArtelo Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/5/2026CALCCalciMedica OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $10.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A($1.89) per shareN/ACALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/ACYCNCyclerion Therapeutics$2.07M6.41N/AN/A$2.31 per share1.33PHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$12.88M-$32.74N/AN/AN/AN/A-1,600.12%-224.62%8/12/2026 (Estimated)CALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)CYCNCyclerion Therapeutics-$3.53M-$1.36N/AN/AN/A-170.11%-62.10%-55.14%8/4/2026 (Estimated)PHIOPhio Pharmaceuticals-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%8/13/2026 (Estimated)Latest ARTL, CYCN, CALC, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ARTLArtelo Biosciences-$0.78-$4.00-$3.22-$4.00N/AN/A5/12/2026Q1 2026CYCNCyclerion Therapeutics-$17.20-$0.76+$16.44-$0.76$0.88 millionN/A5/7/2026Q1 2026PHIOPhio Pharmaceuticals-$0.24-$0.34-$0.10-$0.34N/AN/A3/30/2026Q4 2025CYCNCyclerion Therapeutics-$0.38-$0.19+$0.19-$0.19$0.10 million$1.03 million3/5/2026Q4 2025PHIOPhio Pharmaceuticals-$0.34-$0.15+$0.19-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A1.791.79CALCCalciMedicaN/A1.611.61CYCNCyclerion TherapeuticsN/A1.801.80PHIOPhio PharmaceuticalsN/A18.3218.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%CALCCalciMedicaN/ACYCNCyclerion Therapeutics75.62%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences11.50%CALCCalciMedica41.55%CYCNCyclerion Therapeutics34.30%PHIOPhio Pharmaceuticals0.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences52.33 million2.07 millionNot OptionableCALCCalciMedica3015.80 million9.23 millionNo DataCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataPHIOPhio Pharmaceuticals1011.62 million11.51 millionNot OptionableARTL, CYCN, CALC, and PHIO HeadlinesRecent News About These CompaniesPhio Pharmaceuticals to Participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesMay 27, 2026 | tennessean.comTPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 8, 2026 | finanznachrichten.dePhio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 7, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...April 14, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026April 13, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026April 9, 2026 | finance.yahoo.comPyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology CandidateApril 8, 2026 | jsonline.comJPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 31, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 30, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring ...March 23, 2026 | finance.yahoo.comPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline AdvancementMarch 23, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | newsfilecorp.comNB2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured ConferenceMarch 11, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | finanznachrichten.dePhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTL, CYCN, CALC, and PHIO Company DescriptionsArtelo Biosciences NASDAQ:ARTL$1.43 -0.03 (-2.33%) Closing price 03:58 PM EasternExtended Trading$1.43 +0.00 (+0.28%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.CalciMedica NASDAQ:CALC$0.86 +0.01 (+1.15%) Closing price 03:58 PM EasternExtended Trading$0.85 -0.01 (-1.63%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Cyclerion Therapeutics NASDAQ:CYCN$3.06 +0.06 (+1.87%) Closing price 03:58 PM EasternExtended Trading$3.06 +0.00 (+0.13%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Phio Pharmaceuticals NASDAQ:PHIO$1.14 +0.03 (+2.25%) Closing price 03:58 PM EasternExtended Trading$1.14 +0.00 (+0.44%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
